POSITIVE RESULTS

ImmunoBrain's anti-PD-L1 antibody clears safety bar in early Alzheimer's

Phase 1b data published in Nature Medicine show IBC-Ab002 was well tolerated in 40 patients, with CSF biomarker reductions concentrated in the highest-dose group.

By AppliedXLJuly 14, 2026Trial NCT05551741

Executive Summary

A completed first-in-human trial met its safety primary endpoint, and the sponsor is now emphasizing biomarker findings that were secondary to that safety result.
The therapy works through a peripheral immune checkpoint pathway rather than by directly targeting amyloid or tau, a mechanistically distinct approach within a field otherwise dominated by amyloid-binding antibodies.
The biomarker trends were descriptive and concentrated in the smallest, highest-dose subgroup, so they support further testing rather than establishing a treatment effect.
The company is designing a subsequent study, and whether that trial adds cognitive or clinical endpoints will determine how far this safety-stage result can travel.

The publication

ImmunoBrain published Phase 1b data from its IBC-01-01 study (NCT05551741) of IBC-Ab002 in Nature Medicine, coinciding with a late-breaking presentation at the Alzheimer's Association International Conference. The trial's primary endpoints covered adverse events, serious adverse events, and clinically significant changes across biochemistry, hematology, vital signs, ECG, brain MRI, and suicidality measures, the standard safety battery for a first-in-human antibody study. ImmunoBrain reported the drug was well tolerated at all doses tested, meeting that safety bar. ImmunoBrain+1

Probability of Success

Endpoint Met40%

Completes98%

Clinical Significance39%

Regulatory60%

The design

The randomized, double-blind Phase 1b trial enrolled 40 adults with early Alzheimer's disease across 11 centers in the United Kingdom, Israel, and the Netherlands, running from February 2023 through completion in December 2025. Treatment ran 48 weeks, with cerebrospinal fluid biomarkers, including neurogranin, total Tau, and pTau181, measured as exploratory endpoints against a placebo comparator. IBC-Ab002 is a fully human, Fc-modified anti-PD-L1 antibody engineered for a short half-life, intended to limit chronic immune exposure while still achieving target engagement. NCT05551741+1

The result

ImmunoBrain reported that most patients in the highest-dose cohort showed reductions across the CSF biomarker panel, and that the drug achieved target engagement. Professor Michal Schwartz, whose research at the Weizmann Institute informed the program, said the approach "aims to restore the immune system's ability to protect and repair the brain". The biomarker reductions were secondary and descriptive, concentrated in the smallest subgroup, the highest-dose arm, which is the pattern a safety-primary Phase 1b is designed to generate rather than confirm. ImmunoBrain

The field

Alzheimer's antibody development remains dominated by amyloid-targeting mechanisms: donanemab, lecanemab, and remternetug are all monoclonal antibodies against amyloid beta in active or recent Phase 2-4 trials, and 13 active trials are studying amyloid beta in Alzheimer's disease with a 7% Phase 1 failure rate across 27 completed and 2 terminated trials. IBC-Ab002's anti-PD-L1 checkpoint mechanism sits outside that amyloid- and tau-targeting cluster, working through peripheral immune modulation rather than direct engagement of a pathological brain protein. With no validated disease-modifying mechanism yet established through direct brain-protein clearance in this setting, a checkpoint approach that also improves cognitive or functional outcomes in a larger, controlled study would be the result that distinguishes it from that failure record. ImmunoBrain

What's next

ImmunoBrain said it is designing the protocol for the next phase of clinical development, without stating a timeline. The company's only completed trial to date is this one, so the readout represents the entirety of its Alzheimer's clinical track record. Whether the next study incorporates cognitive endpoints, and at what dose, will determine whether the biomarker trend seen here translates into a clinically measurable effect. ImmunoBrain

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.